We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Metastatic mediastinal carcinoid presenting as superior mediastinal syndrome and treated with peptide receptor radionuclide therapy.
Clinical Nuclear Medicine 2014 January
A 43-year-old man with known superior mediastinal syndrome due to (99m)Tc HYNIC DOTA SPECT/CT and (18)F-FDG PET tracer avid inoperable metastatic carcinoid received peptide receptor based radionuclide therapy (PRRT) with (177)Lu-DOTATATE. Repeat evaluation at 3 months post-therapy demonstrated stable disease with alleviation of patient's symptoms and remarkable improvement in the quality of life. PRRT with (177)Lu-DOTATATE may be an option for inoperable mediastinal carcinoids with superior mediastinal syndrome.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app